The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
New England Journal of Medicine2003Vol. 349(25), pp. 2387–2398
Citations Over TimeTop 1% of 2003 papers
John D. McConnell, Claus G. Roehrborn, Oliver Bautista, Gerald L. Andriole, Christopher Dixon, John W. Kusek, Herbert Lepor, Kevin T. McVary, Leroy M. Nyberg, Harry S. Clarke, E. David Crawford, Ananias C. Diokno, John P. Foley, Harris E. Foster, Stephen C. Jacobs, Steven A. Kaplan, Karl J. Kreder, Michael M. Lieber, M. Scott Lucia, Gary J. Miller, Mani Menon, Douglas F. Milam, Joe Ramsdell, Noah S. Schenkman, Kevin M. Slawin, Joseph A. Smith
Abstract
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
Related Papers
- → The role of combination medical therapy in benign prostatic hyperplasia(2008)46 cited
- → Doxazosin in the treatment of benign prostatic hypertrophy: an update(2006)24 cited
- Landmark studies impacting the medical management of benign prostatic hyperplasia.(2003)
- → Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 Ml or Greater(2006)8 cited
- → Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 ml or Greater(2006)1 cited